Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

Gilead to Let Generic HIV Prevention Drug Enter Market Early (1)

May 8, 2019, 6:41 PMUpdated: May 8, 2019, 8:45 PM

A generic version of Truvada, the only drug approved for HIV prevention in the U.S., will hit the market a year earlier than expected, the drug’s maker Gilead Sciences said in a May 8 SEC filing.

Teva Pharmaceutical Industries will be able to start selling the first generic version of Truvada Sept. 30, 2020. The patent on Truvada was set to expire in late 2021.

The announcement is the result of a 2014 settlement between the drug makers in a dispute over the patents for Truvada and HIV treatment drug Atripla, which has a similar composition, Gilead said. Teva ...